Loading…
Chinese biopharma developing monoclonal antibody drugs, including anti-infective antibody candidates; specifics not fully established.
Chinese biopharma developing monoclonal antibody drugs, including anti-infective antibody candidates; specifics not fully established.
Moat: none
Headquarters: Zhuhai, China · Employees: 843
Size Zhuhai Trinomab Pharmaceutical (688806.SS) is a China Health Care company (Biotechnology) with a market value of $1.58B, the 1559th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥22.90 on 6 Nov 2026.
Growth Revenue grew 237.6% over the last twelve months (peer median +24.8%); the operating margin is -1,195.9% (peer median -5.2%).
Valuation It trades at 199.0× enterprise value to sales against a peer median of 11.8× (4th most expensive of 17).
Capital Return on invested capital runs 110.8 points below its cost of capital (6.3% WACC).
| TTM | FY2025 | FY2024 | FY2023 | |
|---|---|---|---|---|
| Revenue | n/a | CN¥50.8M | CN¥15.1M | CN¥0 |
| Revenue growth | — | +238% | — | — |
| Gross profit | n/a | -CN¥11.9M | -CN¥55.1M | -CN¥62.3M |
| EBITDA | n/a | -CN¥554M | -CN¥460M | -CN¥406M |
| Net income | n/a | -CN¥601M | -CN¥515M | -CN¥446M |
| Free cash flow | n/a | -CN¥599M | -CN¥378M | -CN¥321M |
| Capital expenditure | n/a | CN¥22.4M | CN¥16.3M | CN¥20.9M |
| Total debt | CN¥875M | CN¥696M | CN¥402M | CN¥204M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688806.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -15.7% | -7.7% | 7th lowest of 21 |
| Distance from 52-week high | -56.4% | -43.3% | 5th lowest of 21 |
| Revenue growth (TTM) | +237.6% | +24.8% | 4th highest of 18 |
| Operating margin | -1,195.9% | -5.2% | 2nd lowest of 18 |
| EV / Sales | 199.0× | 11.8× | 4th most expensive of 17 |
| ROIC minus cost of capital | -110.8 pp | -11.2 pp | lowest of 13 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.58B | n/a | +238% | -1,196% | 199.0× | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.59B | -19% | +13% | -712% | 20.6× | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.60B | +5% | +20% | -5% | 2.7× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.57B | n/a | n/a | n/a | n/a | n/a | n/a |
| Precigen PGEN | United States | $1.60B | +6% | +1,875% | -46% | 19.4× | n/a | n/a |
| ANI Pharmaceuticals ANIP | United States | $1.55B | -18% | +31% | 13% | 1.8× | -4.1% | +33.5% |
| PolyPeptide PPGN.SW | Switzerland | $1.62B | +6% | +22% | 7% | 3.3× | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.53B | -41% | +25% | 33% | n/a | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.64B | -44% | +90% | -297% | 231.2× | n/a | n/a |
| Hugel 145020.KS | South Korea | $1.52B | -26% | +17% | 38% | 4.4× | -7.9% | +15.0% |
| uniQure QURE | United States | $1.51B | -22% | +30% | -1,093% | 66.8× | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.67B | -63% | +16% | -427% | 369.5× | n/a | n/a |
| Nurix Therapeutics NRIX | United States | $1.67B | -7% | +739% | 41% | 1.0× | -19.0% | +36.4% |
| Generate Biomedicines GENB | United States | $1.68B | -4% | +56% | -737% | 40.2× | n/a | n/a |
| PELL Bio-Med Technology 6949.TW | Taiwan | $1.49B | +126% | +5% | -1,720% | 1,640.0× | n/a | n/a |
| Kailera Therapeutics KLRA | United States | $1.68B | -40% | n/a | n/a | n/a | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.46B | -13% | +1,084% | -81% | 7.2× | n/a | n/a |
| CanSino Biologics 6185.HK | Hong Kong | $1.71B | -5% | +36% | -4% | 8.7× | n/a | n/a |
| Chengdu Olymvax Biopharmaceuticals 688319.SS | China | $1.71B | -9% | +12% | 8% | 14.8× | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.45B | -38% | n/a | n/a | n/a | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.72B | +45% | +16% | -5% | 6.2× | 45.1% | -2.5% |